Podcasts about roswell park cancer institute

Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. And it most commonly impacts older adults, with higher prevalence among men and African Americans. What are the symptoms and signs that are often subtle or overlooked, leading to delays in diagnosis? What treatment options are available for those diagnosed? In this episode spoke with Jens Hillengass, MD, PhD, chief of the Myeloma and Amyloidosis Service and vice chair of research of the Department of Medicine at Roswell Park Cancer Institute about the importance of early detection, healthy lifestyle strategies, and recent advances in research that offer hope. We then sat down with Jacqueline Henry, BSN, RN, nurse manager for the lymphoma and myeloma department at Roswell Park, about what quality of life looks like for patients, treatment goals, and how to find hope after diagnosis.

Hablo con el Dr. Victor Garcia Gallegos sobre:-El mapeo de endometriosis por ultrasonido y resonancia magnética: qué es, cómo se hace, y qué preparación se necesita la paciente.-La progresión de endometriosis y que tipo de seguimiento se necesita después de la cirugía de escisión.Quien es el Dr. Victor Garcia Gallegos?El Dr. Victor Garcia se graduó de la escuela de medicina de la Universidad de Guadalajara con un Post Doctoral fellowship en UPMC en Pittsbugh, PA y Roswell Park Cancer Institute en Buffalo, NY. Tomó un curso de endometriosis en Ospedale Sacro Cuore Don Calabria en Negrar, Italia.Es radiólogo en el Hospital San Javier desde 2008 y radiólogo en una clínica de excelencia en endometriosis desde 2013, con una práctica privada en ultrasonido diagnóstico enfocado a diagnóstico de endometriosis desde 2013.Para más información en español sobre la endometriosis, ve a mis recursos:MI PÁGINA WEB: www.endoenloprofundo.comINSTAGRAM: @endo.en.lo.profundo

Preview: 2025 Pan-Africa Lung Cancer Meeting The 2025 Pan-Africa Lung Cancer Conference will take place January 31 - February 1, 2025, in Accra, Ghana and represents the first IASLC multidisciplinary lung cancer conference in Sub-Saharan Africa. In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks with the conference co-chairs about this groundbreaking meeting and what attendees will experience at the meeting. Guest: Dr. Chukwumere E. Nwogu is a Professor of Surgery at Roswell Park Cancer Institute and the University at Buffalo Jacobs School of Medicine & Biomedical Sciences Guest: Dr. Jane Sandra Afriyie-Mensah is a Senior Pulmonologist and a Distinguished Academic and Researcher, currently affiliated with the University of Ghana and Korle Bu Teaching Hospital. X: NA

Mentor Moments Season Four Story Moments: Everyone has a story to tell. Dr. Frantz, a graduate of East Aurora High School in 1959, earned his BA from Grinnell College and his MA and Ph.D. from the University of Iowa before joining the University at Buffalo's Counseling Psychology Department in 1967, where he served for over 40 years until retiring in 2008. Throughout his career, he held numerous leadership roles, including Department Chair and Acting Dean, and focused on teaching and research, advising over 80 Ph.D. dissertations and publishing more than 50 works. A specialist in grief counseling, Dr. Frantz worked closely with Dr. Elisabeth Kubler-Ross and founded multiple bereavement support groups, including Compassionate Friends. He led crisis response teams in schools and delivered over 1,300 presentations on bereavement and crisis intervention across the Northeast. Dr. Frantz also served on the boards of several hospice and mental health organizations and remained an active athlete, earning a skydiving certificate and completing solo cross-country bike trips, until a hip replacement sidelined him at age 65. He is supported by his wife Donna and children Karen, Wendy, Brian, and Serena. James P.Donnelly, Jr. grew up in Clarence, NY, a small town near Buffalo, and the hometown of Professor Kiener. Jim received his bachelor's degree in psychology from Allegheny College in Meadville, PA, master's in Social Psychology from Claremont Graduate University in Claremont, CA, and Ph.D. in Counseling Psychology from the University at Buffalo. A licensed psychologist, Jim has held academic, clinical and research positions at Roswell Park Cancer Institute, the University at Buffalo, and Canisius University. Mentoring experiences include many practicum, internship, masters', doctoral, and post-doctoral students. He served on 110 doctoral dissertation committees, chairing 32. His primary focus has been on chronic health conditions, as well as research methods. He is co-author of three widely used books on research methods, author or co-author of more than 150 journal articles, chapters, reviews and abstracts, and has made over 100 national and international presentations at refereed conferences. Jim has been a consultant to the Institute of Medicine, the Centers for Disease Control, Children's Hospice International, among others. He is Professor Emeritus in the Department of Counseling and Human Services and continues as Director of Measurement and Statistics at the Institute for Autism Research at Canisius. Welcome to Mentor Moments, the podcast where distinctive journeys shape the individuals we become. Join us for engaging counseling conversations that delve deep into personal journeys while focusing on pressing professional issues. In this season of Mentor Moments, we're honored to feature remarkable individuals who not only introduce you to the world of rehabilitation counseling but also tackle current topics and issues that matter. Each episode invites you into the minds of our guests as they share their unique perspectives. Follow us at: Email: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠mentor.momentsMRA@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Instagram: @mentor.moments Website: https://www.mraeasternchapter.com/maryvillerc

In this episode of ASTCT Talks, Dr. Muhammad Salman Faisal is joined by Dr. Jens Hillengass. Dr. Hillengass discusses the latest advancements in CAR T cell therapy, focusing on its application in early-line settings following the results of the CAR-TITUDE 4 and KarMMa-3 trials. Tune in as he shares insights on the efficacy, patient selection and future directions of CAR-T cell therapy in multiple myeloma. This episode is supported by Johnson & Johnson. Don't miss out on this informative discussion with one of the leading experts in the field. About Dr. Jens Hillengass Jens Hillengass, MD, PhD, is Professor of Oncology and Chief of the Myeloma and Amyloidosis Service at Roswell Park Cancer Institute, Buffalo, NY. Previously, he was the head of the autologous stem cell transplant program and the deputy chief of the multiple myeloma section at the University Hospital of Heidelberg, Germany. He earned his medical degree, residency, and fellowship at Heidelberg University, and completed a research fellowship at the National Cancer Institute. Dr. Hillengass co-chairs the bone and imaging group of the International Myeloma Working Group and serves on the Multiple Myeloma guideline committee at the National Comprehensive Cancer Network. About Dr. Muhammad Salman Faisal Dr. Muhammad Salman Faisal is currently a fellow at Roswell Park Comprehensive Cancer Center, in his third year of training, with keen interest in myeloma, CAR-T and access to care.

Do you know anyone with dementia? If you don't, you will. We humans are living longer and healthier lives. There are more healthy 75 year old people alive now than there ever have been. However, the number of people with dementia is sky rocketing as well. Enter Dr. Mechtler…Dr. Lazslo Mechtler is the Medical Director of Dent Neurologic Institute, the Chief of Neuro-Oncology at Roswell Park Cancer Institute and is also the Director of the DENT Headache Center, Neuro-Oncology Center, and Cannabis Clinic.Dr. Mechtler gives us a fantastic review of dementia, and Alzheimer's disease. Then he talks about the work they are doing at the DENT Institute to treat dementia with cannabinoids.DENT Neurologic Institute - Cannabis Clinic - WebsiteLazlo Mechtler - LinkedInLazlo Mechtler - DENT-website profileMusic by:Christopher Cros - Sailing -YouTubeAdditional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute. At the meeting, Dr. Jagannath presented results of the phase 1/2 LINKER-MM1 trial of linvoseltamab, a CD3-directed B-cell maturation antigen (BCMA) antibody under investigation for relapsed/refractory multiple myeloma. In this follow-up conversation, Dr. Jagannath shares further insights into the trial, including: • The study design, which includes triple-class–refractory patients • The unique dosing schedule of linvoseltamab, which reduces the frequency of administration to improve patient convenience • The response, survival, and measurable residual disease (MRD) negativity outcomes demonstrated in the trial, including among high-risk patients • Management of side effects, including cytokine release syndrome (CRS), neutropenia, anemia, and infections • The future role of linvoseltamab in the treatment landscape for relapsed/refractory multiple myeloma as it advances through investigation • And more!

J. Craig Venter, PhD, ( https://www.jcvi.org/about/j-craig-venter ) is regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research. Dr. Venter is founder, chairman, and CEO of the J. Craig Venter Institute (JCVI), a not-for-profit, research organization with approximately 120 scientists and staff dedicated to human, microbial, synthetic, and environmental genomic research, and the exploration of social and ethical issues in genomics. Dr. Venter began his formal education after a tour of duty as a Navy Corpsman in Vietnam from 1967 to 1968. After earning both a Bachelor of Science in biochemistry and a PhD in physiology and pharmacology from the University of California at San Diego, he was appointed professor at the State University of New York at Buffalo and the Roswell Park Cancer Institute. In 1984, he moved to the National Institutes of Health campus where he developed expressed sequence tags or ESTs, a revolutionary new strategy for rapid gene discovery. In 1992, Dr. Venter founded The Institute for Genomic Research (TIGR, now part of JCVI), a not-for-profit research institute, where in 1995 he and his team decoded the genome of the first free-living organism, the bacterium Haemophilus influenzae, using the new whole genome shotgun technique. In 1998, Dr. Venter founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed. This research culminated with the February 2001 publication of the human genome in the journal, Science. He and his team at Celera also sequenced the fruit fly, mouse, and rat genomes. Dr. Venter and his team at JCVI continue to blaze new trails in genomics. They have sequenced and analyzed hundreds of genomes, and have published numerous important papers covering such areas as environmental genomics, the first complete diploid human genome, and the groundbreaking advance in constructing the first self-replicating bacterial cell using synthetic DNA. Dr. Venter is one of the most frequently cited scientists, and the author of more than 280 research articles. He is also the recipient of numerous honorary degrees, public honors, and scientific awards, including the 2008 United States National Medal of Science, the 2002 Gairdner Foundation International Award, the 2001 Paul Ehrlich and Ludwig Darmstaedter Prize, and the King Faisal International Award for Science. Dr. Venter is a member of numerous prestigious scientific organizations including the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Society for Microbiology. Dr. Venter is also a serial entrepreneur who has co-founded several companies including Synthetic Genomics, Inc., now Viridos and Human Longevity, Inc. (HLI). Dr. Venter's newest book "The Voyage of Sorcerer II: The Expedition That Unlocked the Secrets of the Ocean's Microbiome" was recently released on September 12, 2023 - https://www.amazon.com/Voyage-Sorcerer-II-Expedition-Microbiome/dp/0674246470 Support the show

Though Richard Satterwhite is best known as an actor and director, his work at Roswell Park Cancer Institute as a Patient Engagement Specialist could be considered far more significant, since it is there that he makes an almost daily contribution to the health and well-being of so many men in our area. But, of course, we talk also about his life and his experiences in improv, and the stage and film performances that have made his face recognizable throughout our town.   Also, we once again “Step Out With Sabrina”!

In this latest episode of ASTCT Talks, Dr. Rebecca Gonzalez sits down with Dr. Katie Gatwood and Dr. Timothy Porter to kick off National Pharmacy Month by discussing the clinical implications of post-transplant cyclophosphamide (PTCy) use outside of the haploidentical setting. They delve into their respective cancer centers' primary donor sources for match unrelated donors and the breakdown of conditioning intensity within their hematologic patients. They delve into the future of PTCy discussing the potential for earlier de-escalation of immunosuppressants to limit drug-related toxicities and optimize patient outcomes as well as important supportive care considerations. Despite the exciting prospects, the need for robust prospective data before implementation is emphasized. About Dr. Rebecca Gonzalez Dr. Rebecca Gonzalez (@xnyerin) received her Doctor of Pharmacy degree from the University of Florida College of Pharmacy. She completed her PGY2 Oncology residency at West Virginia University in Morgantown, West Virginia. Following post-doctoral training, Dr. Gonzalez was a Hematology Clinical Pharmacist at the Roswell Park Cancer Institute prior to transitioning to Moffitt Cancer Center in 2015. She is Board Certified in Oncology Pharmacy and currently practices as a Clinical Pharmacist in Blood and Marrow Transplant/Cellular Immunotherapy at Moffitt in Tampa, Florida. She was a past chair of the ASTCT Pharmacy Program Planning Committee in 2021-2022 and has been involved in several ASTCT teaching activities since 2017. Her interests include survivorship, GVHD, supportive care and infectious disease complications related to transplant and immune cellular therapy. About Dr. Katie Gatwood Dr. Gatwood is a Board-Certified Oncology Pharmacist and Clinical Pharmacist Specialist specializing in Adult Stem Cell Transplant and Cellular Therapy at Vanderbilt University Medical Center. She holds a Doctor of Pharmacy degree from the University of Michigan and completed her residency training at the University of North Carolina Health Care. Dr. Gatwood is the chair-elect of the ASTCT Pharmacy SIG Sterring Committee. She was also awarded the 2021 ASTCT Pharmacy SIG New Practitioner Award and is passionate about clinical research and education, with a focus on VOD, CAR T-cell therapy, and oncology pharmacists' role in ambulatory care. About Dr. Timothy Porter Dr. Timothy Porter is a Board-Certified Oncology Pharmacist and practices as a Clinical Pharmacy Specialist in Blood and Marrow Transplantation and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, FL. He earned a Doctor of Pharmacy degree from Duquesne University School of Pharmacy and then completed a PGY1 Pharmacy Residency at Allegheny General Hospital in Pittsburgh, PA, followed by a PGY2 Oncology Pharmacy Residency at The Johns Hopkins Hospital in Baltimore, MD. He then practiced as a Clinical Pharmacy Specialist in Blood and Marrow Transplantation and Cellular Therapy at The Johns Hopkins Hospital before transitioning to Moffitt Cancer Center in 2022. Dr. Porter is a member of the ASTCT Pharmacy SIG Education Committee and serves as the Journal Club Lead. His professional interests include management of infectious complications in immunocompromised patients, GVHD, CAR T-cell therapy, clinical research, and education.

A new research paper was published in Oncotarget's Volume 14 on June 19, 2023, entitled, “Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.” Androgen deprivation therapy (ADT) can lead to metabolic syndrome (MS) and is implicated in ADT-resistance. Metformin showed antineoplastic activity through mTOR inhibition secondary AMPK-activation. To investigate whether metformin mitigated ADT-related MS, researchers Devalingam Mahalingam, Salih Hanni, Anthony V. Serritella, Christos Fountzilas, Joel Michalek, Brian Hernandez, John Sarantopoulos, Paromitta Datta, Ofelia Romero, Sureshkumar Mulampurath Achutan Pillai, John Kuhn, Michael Pollak6, and Ian M. Thompson from the University of Texas Health Science Center, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Roswell Park Cancer Institute, Mays Cancer Center at University of Texas Health, Audie Murphy VA Hospital, McGill University, and Christus Health conducted a randomized double-blind phase II trial of metformin 500 mg TID or placebo in non-diabetic patients with biochemically-relapsed or advanced prostate cancer (PC) due for ADT. “To test these hypotheses, we conducted a phase II randomized, placebo-controlled, prospective study of metformin vs. placebo in patients with advanced, castrate sensitive PC treated with ADT (NCT:01620593).” Fasting serum glucose, insulin, PSA, metformin, weight, and waist circumference (WC) were measured at baseline, week 12 and 28. The primary endpoint was a group of MS metrics. Secondary endpoints include PSA response, safety, serum metformin concentrations and analysis of downstream an mTOR target, phospho-S6-kinase. Thirty-six men were randomized to either metformin or placebo. Mean age was 68.4. Mean weight, WC and insulin levels increased in both arms. At week 12 and 28, no statistical differences in weight, WC or insulin were observed in either arm. No significant difference in percentage of patients with PSA

Dr. Lynne Maquat is the J. Lowell Orbison Endowed Chair and Professor of Biochemistry and Biophysics in the School of Medicine and Dentistry, Director of the Center for RNA Biology, and Chair of Graduate Women in Science at the University of Rochester. Research in Lynne's lab focuses on human diseases and what causes diseases in our cells. She is working to understand how cells function normally, determine what causes diseases, and develop treatments for diseases. In particular, she has been studying a process in cells that causes about one third of all inherited diseases, like cystic fibrosis and Duchenne muscular dystrophy, as well as one third of all acquired diseases, including cancer. Lynne has a Labrador retriever whom she loves taking on walks through the lovely parks and woods in Rochester, New York. She also enjoys exercising through yoga, lifting weights, and doing cardio. She received her BA in Biology from the University of Connecticut and her PhD in Biochemistry from the University of Wisconsin-Madison. Lynne conducted postdoctoral research at the University of Wisconsin-Madison, and she worked as a faculty member at the Roswell Park Cancer Institute for 19 years before joining the faculty at the University of Rochester. Lynne has received numerous awards and honors during her career, including the International RNA Society Lifetime Achievement in Science Award, the Canada Gairdner International Award, the William Rose Award from the American Society of Biochemistry and Molecular Biology, the Athena Award from the Women's Council of the Rochester Business Alliance, a MERIT Award from the NIH, the Presidential Diversity Award from the University of Rochester, the RNA Society Lifetime Achievement Award in Service, and many others. She was also named a Member of the U.S. National Academy of Sciences, a Fellow of the American Association for the Advancement of Science, a Fellow of the American Academy of Arts and Sciences, and a Batcheva de Rothschild Fellow of the Israel Academy of Sciences and Humanities. Lynne discusses her experiences in life and science with us in this interview.

Carol DeNysschen is a Full Professor and Dean of the School of Professions at SUNY Buffalo State College. Carol's heavy science background opened multiple career doors. Her research focus, in her spare time, is with cancer patients at Roswell Park Cancer Institute and she uses her love of nutrition and exercise to help cancer survivors prevent cancer recurrence. Carol was Department Chair of the Health, Nutrition, and Dietetics department for the past 6 years until she stepped into the Dean's role. She is an Adjunct Assistant Professor at Roswell Park Cancer Institute where she is an active member of the Survivorship Research Department and created a program for adolescent and young adult cancer survivors centered around healthy behaviors. Carol has a strong background in Biology, Public Health, Exercise Science, and Nutrition, and to round out her educational portfolio, she earned an MBA in 2021. Carol or Dr. DeNysschen is an active Board Member of FeedMore WNY and sits on the Programs and Services subcommittee. Recently she was appointed to the Finance Committee as the organization proceeds with a capital campaign project. On top of this, she holds an Executive Chair position of HOPE Haiti out of Rochester. As Past-President of her State level Professional Organization (NYS Academy of Nutrition and Dietetics) – she led the board through operational changes that brought the organization out of a budget deficit, created a diversity liaison position, and strategically hired a lobbyist for advancement towards licensure in the state. She has received several notable awards including the SUNY Chancellor's Award for Excellence in Faculty Service, the Buffalo State President's Award for Excellence in Faculty Service, the Buffalo State President's Award for Excellence in Research, Scholarship and Creativity, the President's Caring Bengal's Award, and the national Abbott Nutrition Award in Women's Health. Most recently she was featured by Business First with the “Making Buffalo Better” recognition for her active commitment and efforts to combat food insecurity. In her spare time, her long-time hobbies include running (she qualified for and ran the Boston marathon 5 times and completed over 20 marathons), biking and recently she became a rower and has found it a whole new challenge, admitting that she certainly has work to do on her rowing form!!!! How to contact Dr. DeNysschen: denyssca@buffalostate.edu Your Body Is Your Business! Shawn and Laura are professionals based out of Atlanta “Trust, respect, passion, & integrity. These core values can be offered on your journey to optimize your lifestyle changes. Our goal is to provide you with the tools, knowledge, & confidence to provide you the edge over your competition. ” Interested? Click on the link below! Use the link below to access this podcast on #applepodcasts, discount on #thorne #supplements, nutrition services, and my professional experience (Linkedin) https://linktr.ee/rootsrd Sponsors: If you are interested in sponsoring the show please contact Shawn at sportsrd607@gmail.com #podcast #nutrition #sportnutrition #strength #mentalhealth #sportsmedicine #atc #leadership #strengthandconditioning #performance #athletes #coordinatedprogram #educator #professor #undergraduate #SUNYBuffalostate #academia --- Support this podcast: https://podcasters.spotify.com/pod/show/shawn-pitcher/support

Dr. Andrei Gudkov of the Roswell Park Cancer Institute in Buffalo, NY discusses the research paper he co-authored that was published by Aging (Aging-US) in Volume 9, Issue 8, entitled, "p16(Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli." DOI - https://doi.org/10.18632/aging.101268 Correspondence to - Olga Chernova - ochernova@tartiscorp.com and Andrei Gudkov - andrei.gudkov@roswellpark.org Abstract: Constitutive p16Ink4a expression, along with senescence-associated β-galactosidase (SAβG), are commonly accepted biomarkers of senescent cells (SCs). Recent reports attributed improvement of the healthspan of aged mice following p16Ink4a-positive cell killing to the eradication of accumulated SCs. However, detection of p16Ink4a/SAβG-positive macrophages in the adipose tissue of old mice and in the peritoneal cavity of young animals following injection of alginate-encapsulated SCs has raised concerns about the exclusivity of these markers for SCs. Here we report that expression of p16Ink4a and SAβG in macrophages is acquired as part of a physiological response to immune stimuli rather than through senescence, consistent with reports that p16Ink4a plays a role in macrophage polarization and response. Unlike SCs, p16Ink4a/SAβG-positive macrophages can be induced in p53-null mice. Macrophages, but not mesenchymal SCs, lose both markers in response to M1- [LPS, IFN-α, Poly(I:C)] and increase their expression in response to M2-inducing stimuli (IL-4, IL-13). Moreover, interferon-inducing agent Poly(I:C) dramatically reduced p16Ink4a expression in vivo in our alginate bead model and in the adipose tissue of aged mice. These observations suggest that the antiaging effects following eradication of p16Ink4a-positive cells may not be solely attributed to SCs but also to non-senescent p16Ink4a/SAβG-positive macrophages. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.101268 Keywords - aging, macrophage, senescent cell, p16(Ink4a), beta-galactosidase About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at http://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/agingus​ LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Aging-US is published by Impact Journals, LLC: http://www.ImpactJournals.com​​ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

In this episode of Occupation Station, 2008 ACPHS grad Shawn Leland talks about the personal, educational and professional ways he has been inspired to help people live longer, healthier lives. Some of that inspiration came to him through a clerkship rotation that didn't go as planned and instead landed him at Roswell Park Cancer Institute. While engaged in his studies, he was also seeing real health challenges in people he loved. He witnessed how important drug therapies were in helping them to live their best lives. After graduation, Leland says he experienced a big realization during a European Society of Medical Oncology conference and got an idea that led him to pull together the right researchers and financers to create a tumor agnostic drug development strategy. Even the name of Leland's company, Elevation Oncology, comes from a very inspired place. Leland has frequently been inspired along his career path; now he shares that inspiration with current and prospective ACPHS students. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Occupation Station, 2008 ACPHS grad Shawn Leland talks about the personal, educational and professional ways he has been inspired to help people live longer, healthier lives. Some of that inspiration came to him through a clerkship rotation that didn't go as planned and instead landed him at Roswell Park Cancer Institute. While engaged in his studies, he was also seeing real health challenges in people he loved. He witnessed how important drug therapies were in helping them to live their best lives. After graduation, Leland says he experienced a big realization during a European Society of Medical Oncology conference and got an idea that led him to pull together the right researchers and financers to create a tumor agnostic drug development strategy. Even the name of Leland's company, Elevation Oncology, comes from a very inspired place. Leland has frequently been inspired along his career path; now he shares that inspiration with current and prospective ACPHS students. Learn more about your ad choices. Visit megaphone.fm/adchoices

As we continue our Cholangiocarcinoma Series I am excited to welcome to the show, Milind Javle, M.D. Milind Javle is a medical oncologist from Houston, TX. He is currently the Hubert L. and Olive Stringer Professor at UT MD Anderson Cancer Center, he is also the current chair, NCI Task Force, Hepatobiliary Cancers, former chair of the International Cholangiocarcinoma Research Network, Vice President of the Cholangiocarcinoma Foundation: Clinical and Scientific Advisory Board. He graduated from Grant Medical College, Mumbai, India and completed his residency in SUNY, Buffalo, NY, and oncology training at Roswell Park Cancer Institute, NY. He has authored over 200 articles in peer-reviewed literature, has been the principal investigator for several phase 1-3 clinical trials and served in an advisory capacity to pharmaceutical companies, regulatory and networking bodies. He has held leadership positions in the American Society of Clinical Oncology and Hepatobiliary Conventions. He has led/ participated in pivotal clinical trial of infigratinib and ivosidenib which led to FDA approvals and is regarded as one of the international leaders in this field. Listen in as Dr. Javle helps us Get to know Cholangiocarcinoma.  Learn More About Cholangiocarcinoma At: https://cholangiocarcinoma.org/ Visit http://www.onairadvocate.com for information on all of our products, services & resources. 

In this episode of Occupation Station, 2008 ACPHS grad Shawn Leland talks about the personal, educational and professional ways he has been inspired to help people live longer, healthier lives. Some of that inspiration came to him through a clerkship rotation that didn't go as planned and instead landed him at Roswell Park Cancer Institute. While engaged in his studies, he was also seeing real health challenges in people he loved. He witnessed how important drug therapies were in helping them to live their best lives. After graduation, Leland says he experienced a big realization during a European Society of Medical Oncology conference and got an idea that led him to pull together the right researchers and financers to create a tumor agnostic drug development strategy. Even the name of Leland's company, Elevation Oncology, comes from a very inspired place. Leland has frequently been inspired along his career path; now he shares that inspiration with current and prospective ACPHS students.

Join Kristie and Mike as they welcome special guest, Sue Morreale, on the next episode of Where's My Sage?!! Susan believes a woman should always appreciate herself + honor her soul in everything she does. That philosophy has helped her create a business that inspires women to recognize their individuality, personal style and strength. She has owned and operated her businesses with her daughter, Her Story (formerly Lotions + Potions) + Her Sanctuary. What began in 1990 as retail business has grown into a destination where you can heal your mind-body-soul. She has also designed a line of jewelry, the Her Story Jewelry Collection. Taking care of yourself inside + out has always been important to Susan. She graduated from Niagara County Community College as an RN in 1985 and began her journey of nursing as a charge nurse at Niagara Falls Memorial medical Center on their Med Surg floor where she later went on to create their IV team. Sue is a true believer in integrative health, working part time at a local functional medical practice, Cardea Health Integrative. Susan is a true wellness warrior and advocate for the fight against breast cancer and continues to empower and inspire women to live their best possible life. She was recognized by the American Cancer Society for her wellness work in 2012 and has also been commissioned by Roswell Park Cancer Institute to create a healing sanctuary in their resource center.

Dr. Mikhail V. Blagosklonny, M.D., Ph.D., Editor-in-Chief of Oncotarget, and Professor, at Roswell Park Cancer Institute, published "The goal of geroscience is life extension" which was selected as the Featured Cover Paper for Volume 12 Issue 3 and reported that although numerous drugs seemingly extend healthspan in mice, only a few extend lifespan in mice and only one does it consistently. Some of them, alone or in combination, can be used in humans, without further clinical trials. Dr. Mikhail V. Blagosklonny from The Roswell Park Cancer Institute said, "Although we do not know everything about aging, we now know enough to start its pharmacologic suppression using clinically approved drugs." Published in 2010, these opening words of the paper entitled "Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal" are still relevant today. Hyperfunction of these signaling pathways directly drive all age-related diseases, which are manifestations of aging. We just need clinically available inhibitors of these signaling pathways to extend both healthspan and lifespan, by slowing aging. A mere extension of healthspan is not enough: drugs that fail to extend lifespan in mice will fail to extend lifespan in humans, if used as a monotherapy. Yet, in rational combinations with life-extending drugs, "healthspan-only" drugs may extend lifespan further. In this Oncotarget publication, Dr. Blagosklonny reviews drugs that extend lifespan and healthspan in mammals, in contrast to those that may affect only healthspan without lifespan, and discusses how to proceed with clinical application of lifespan-extending drugs. Blagosklonny concluded in their Oncotarget Research Perspective, "If we want to live longer, we have no choice, but to use drugs such as rapamycin, which extends life in short-lived mammals and is approved for humans use. After all, humans are mammals, and there is no reason to think that they will not work in humans." Please note: This review is intended for a professional audience. This article does not represent medical advice or recommendations to patients. The media should exercise caution and seek expert medical advice for interpretation, when referring to this article. Medical doctors interested in this topic may e-mail the author at Blagosklonny@rapalogs.com or follow on Twitter @Blagosklonny Sign up for free Altmetric alerts about this article DOI - https://doi.org/10.18632/oncotarget.27882 Full text - https://www.oncotarget.com/article/27882/text/ Correspondence to - Mikhail V. Blagosklonny - Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com Keywords - aging, longevity, rapamycin, mTOR, metformin About Oncotarget Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957x105

Dr. Alysia V. Kwiatkowski is an Assistant Professor of Medicine, Allergy, Immunology & Rheumatology at the University at Buffalo (UB). She is the Senior Associate Program Director and Director of Curriculum Development for the Internal Medicine Training Program and an education development specialist for UB's Medical Education and Educational Research Institute. Dr. Kwiatkowski is also the Site Director of Internal Medicine & Advanced Medicine Clerkships at Erie County Medical Center. She completed her Masters of Science at Roswell Park Cancer Institute and her DO in Medicine from New York Institute of Technology College of Osteopathic Medicine. Dr. Kwiatkowski then completed Residency in Internal Medicine from the Albany Medical Center where she was also the Chief Resident. She then pursued a Fellowship in Rheumatology from Rush University Medical Center, where she received certification in teaching excellence. In 2018, Dr. Kwiatkowski was invited by the Rheumatology Research Foundation as a fellow in training and furthered her research in medical education comparing team-based learning with non-interactive learning and the incorporation of musculoskeletal examination workshops into rheumatology electives. Her awards include the Psi Sigma Alpha from the National Osteopathic Scholastic Honor Society and Sigma Sigma Phi from the National Osteopathic Service Fraternity, in addition to awards for recognition of her skills as an educator. If there is one thing we should take away from this conversation with Dr. Alysia Kwiatkowski, it is that we have a voice, and we need to use it. Today, we realize how we as learners are the ultimate stakeholders in medical education therefore our voice is just as important if not more. Dr. Kwiatkowski's mission in medicine is to improve education and leadership for her students and generations to come. And today, we'll learn from her story that the most powerful thing we can do is to get the best training we can, give back to our community, and make a positive impact. Pearls of Wisdom: 1. Get the best training you can, and give back to your community. There is value in thinking beyond ourselves. 2. Have a voice, and use it (even when we feel intimidated). We as the learners are a valued member of decision-making as the ultimate stakeholders in medical education. 3. The mentor's role is to help us set and achieve goals. As mentees, our role is to be open and honest with them. 4. There is no failure, just feedback.

Maria has 25 years of experience practicing and teaching various forms of meditation and mindfulness. Maria's work with her clients incorporates introspective and compassionate work with the goal of getting to the root cause of stress and then engaging in effective management strategies. She has mentors from every corner of the globe and has launched Mindfulness Training programs for major organizations including FIFCO USA, UB School of Medicine and Roswell Park Cancer Institute. You can find her at www.mindfulnesstrainingsrc.com

Dr. Hayes interviews Dr. Bloomfield on her role as one of the first physician-scientists to investigate treatment for acute myeloid leukemia (AML).   TRANSCRIPT The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. [MUSIC PLAYING] Welcome to JCO's Cancer Stories-- The art of Oncology brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content and offering enriching insight into the role of cancer care. You can find all of the shows, including this one, at podcast.asco.org. [MUSIC PLAYING] Welcome to today's version of the ASCO Cancer Stories podcast. Today, my guest on the podcast is Dr. Clara Bloomfield. Dr. Bloomfield was instrumental in the early studies investigating the biology of leukemias and lymphomas, and also the interaction between various molecular markers and treatment. She founded the Correlative Science Committee of The Cancer and Leukemia Group B, which is now designated the Alliance in the 1980s. And I believe that was probably the first such committee in the cooperative groups, and she chaired it for at least 25 years. Her work resulted in numerous groundbreaking insights that led to changes in practice. Personally, and having worked with her for several of those years in CALGB, I really consider her one of the first investigators to perform what we now blithely called, quote, "translational," end of quote, science in cancer. Dr. Bloomfield was born in New York City, but her father, who was an expert in labor and industrial relations, moved the family to Washington, DC during World War II. And after the war, he then took a position at the University of Illinois, leading Dr. Bloomfield to have a nearly lifelong association with the Midwest. She attended undergraduate school at the University of Wisconsin, but then graduated from San Diego State College during a brief foray to the West Coast. She returned to the Midwest to attend medical school at the University of Chicago, and then completed her internal medicine residency and her medical oncology fellowship at the University of Minnesota, where she stayed on faculty until 1989. She then became chair of the Department of Medicine at Roswell Park Cancer Institute in Buffalo for the next eight years, and then moved to the Ohio State University, where she accepted the position as director of the comprehensive and now designated the James Cancer Center. She's remained at OSU and is currently a distinguished university professor and the William G. Pace II professor of cancer research and a senior advisor at the OSU James Cancer Center. Dr. Bloomfield has authored hundreds of peer-reviewed papers. She is an elected member of the National Academy of Medicine and the National Academy of Sciences. She's, frankly, won just too many awards that I can name here. But importantly, she served on the ASCO board of directors, and in 2009, she gave the David A. Karnofsky Memorial Lecture, the highest honor our society can bestow. Clara, welcome to our program. Thank you. You know, I have a lot of questions for you, many of which I thought about that I should have asked you 30 years ago or so when we first started working together in CALGB. But I think the biggest one is, how did you get interested in leukemia in the first place? Were any particular personal insights that resulted in the basis of your career? Or was it just happenstance? I think it happened because in grade school, I had a number of classmates who developed leukemia. And they were sent to the National Cancer Institute because people in those days didn't treat leukemia. And they returned with steroid-bloated faces and soon died. And I thought, well, wouldn't it be cool to develop medicine that could save kids from dying? I'd already decided to become a doctor, so seeing the real-life effects of cancer helped shape my early desire to become an oncologist. So that must have been about the same time, a little bit after, that Drs. Frei, and Freireich, and Holland started combination therapy for leukemia. They must have had a big impact on your career then. I don't remember. [? No, ?] I'm kidding. Actually, the other question-- I know that you spent some time at Stanford and ran into Henry Kaplan. And there was a cute anecdote, I think, about how you presented with his backing at one of the conferences. Can you tell us a little bit about Dr. Kaplan and your work with him? Sure. During my junior and senior years in medical school, I did a sub-internship at the University of California at San Francisco. And I saw a patient with Hodgkin's disease who was not being treated with curative intent. And I said to the attending, you're not giving this patient modern therapy. And the attending replied, well, if you're so smart, we'll have you do grand rounds on how to treat Hodgkin's disease. Remember, I was a medical student. So I called Professor Henry Kaplan at Stanford for advice. And he was great, and he said, well, they never want me to come. I'd be happy to come and help you give grand rounds. So to the surprise of my attending and awe as a medical student, I conducted grand rounds at the University of California at San Francisco with Professor Kaplan. That must have been a big surprise. Yes, I think it was. Actually, one of my interviews has been with Saul Rosenberg, and he also had some great stories about Dr. Kaplan when they first started giving chemotherapy at Stanford. And Kaplan was apparently quite supportive of doing this. So-- Yes, he was. --I never got to meet him. Yeah. Another question, again, about the time you entered the field, I referred to what I consider the big three, Frei, Freireich, and Holland, but their therapy was really pretty empiric for leukemia. It was just hoping that giving more drugs would be better than one drug. But you really got us into genetics. What made you do that? I mean, what made you think that we could treat people, really, with precision medicine better than we did in those days? Well, my second research project I had as a fellow, which was presented at ACR in May of 1972 and published in April of 1973, involved daunorubicin-prednisone therapy for AML. And in that, the question was raised in patients without Auer rods, the question were these of CML in blast crisis was raised, so chromosome studies were done. And this got me started studying cytogenetics in leukemia, and subsequently molecular genetics. And also, you asked if I had a role model, and the answer is no. I did not have a role model. I know that very early on in your career, you published a very controversial paper suggesting that the Philadelphia chromosome could be found in acute lymphocytic leukemia, which at the time, I think, was probably heresy, since it had been associated with CML. I understand that you interacted with Avery Sandberg, the [? tube ?] giant. I remember hearing about Avery Sandberg when I was a freshman in college in genetics, and he supported you. What was the background behind that? At the 1975 ASH meeting, I presented an abstract, I gave a talk on the Philadelphia chromosome-- on Philadelphia chromosome positive acute leukemia. And after that talk, many prominent cytogeneticists raised questions about the validity of my findings. However, Avery Sandberg, while surprised by the findings, said, she may be right. Sometimes these youngsters get things that we've missed. And did you walk out beating your chest? That must have been quite a moment. I was happy that he-- I was happy that he supported me. Well, I want to go on to some of your other work, but I'm going to tell you that in our fellows clinical conference here a couple of weeks ago, which I attend every week, one of the fellows started talking about FLT3 leukemia. But his comment was leukemia is described as the most genomically defined cancer. And I didn't bring it up at that meeting, but I thought, you owe Clara Bloomfield for that statement. You should be really proud of your work. I almost picked up the phone to call you to tell you that our fellows don't know that you did the work. They should, and that's why we're doing these podcasts. So the only thing-- I know you challenged dogma was the treatment of older patients with leukemia. And as you and I both get older, I think it becomes more near and dear to our heart. Can you give some insight into that? I mean, my impression, when I was a fellow, was we just kind of said, oh, you're over 60, it's not worth treating you. But I think you really challenged that and changed that dogma. So ASH [INAUDIBLE] the third paper I published and project that I started on when I started as a fellow, because I was asked to do this by one of my attendings, was to look at treating older patients with acute leukemia. In the early 1970s, which we're talking about, it was considered that standard intensive treatment of patients with acute leukemia over the age of 40 or 50 years of age was malpractice or at least wrong. So when I was asked to look at this, we had a few patients over the age of 60 with AML treated with what was then standard intensive chemotherapy. So I compared the outcome of patients aged 21 to 40, 41 to 60, and 61 to 86 years. And what I found was that patients aged 41 to 60 and greater than 60 responded equally well. As a result, we said that patients over 60 should be treated. This meant that what we did was told major researchers in leukemia that they were wrong. This caused quite a stir, as you might imagine. And interestingly, within the next five to 10 years, they all came back to me and said they had been wrong. In that regard, I watched you in CALGB. I was on the solid tumor side, obviously, but you were really a pioneer in organizing and conducting translational research and correlative research in leukemia in the cooperative groups. When you started, I don't think there was any of that, was there? Were there a lot of obstacles to doing that? I think everybody just takes it for granted now, especially with so-called precision medicine. But what did you have to do to get that started at CALGB? From 1982 on, I was chair of the Correlative Science Committee in Cancer and Leukemia Group B. In 1984, I actually started to have NIH grant to support correlative science in the CALGB cooperative group. In 1984, we already had a trial in Cancer and Leukemia Group B to do cytogenetics in acute leukemia. I mean, a lot of this work was based on my work in cytogenetics. And while there may have been clinicians who were opposed, I had the support of important people like Professor Janet Rowley and the cytogeneticists at the CALGB institutions. And there really were not significant obstacles that I can remember. Of course, if there were people who tried to block me, I probably didn't care and worked around them. I'm sure that's true. I am too. This is part of what-- when you're one of the few women, as I was when I started in the field, I mean, I suppose I was always getting blocked about things, I just don't think much about it. I didn't then and I don't now. That segues into my final question, actually. And these days, more than half of our medical students are women. More than half of our residents are women at the University of Michigan. More than half of our fellows in hem-onc are women. Increasingly, the faculty is there. But when you started, you were really a pioneer, I think, in introducing women into clinical and laboratory research in oncology and academic medical leadership. And I just want to list the things, because I don't think you will, that I think you've done. First, I understand you were the first woman chief resident at the University of Minnesota, the first woman full professor in medicine at the University of Minnesota, one of the first women chairs of medicine in the United States when you were at Roswell Park, the third woman to be director of an NCI-designated Cancer Center. And frankly, as I was preparing this, I was on an airplane and I was watching A Matter of Sex about Ruth Bader Ginsburg, and I thought, this is a really familiar story. Do you have any war stories that you thought were particularly telling when you began? And especially, for example, I know you have a story about what the dean told you when you were considering becoming an academic professor. Do you have anything to inspire the people listening to this podcast? I'm sure there were some probably pretty aggressive war stories that I don't remember. And as I said, I don't tend to think about what happened in the past since I'm trying to keep up with the present. But I guess there are a couple of stories. Unbelievably, when I was a medical student, I always sat in the front row in class because that was the only way I could see the slides. And the dean, medical school dean, called me into his office and said it was not ladylike to sit in the front row. And I told him-- it's unbelievable really-- I told him that when he became a lady, he could tell me how to act like one, and walked out on him. But the more important story, I suppose-- that I can remember-- is that when I was appointed an associate professor, which occurred three years after I became an assistant professor, so the head of medicine called me in and said, congratulations, Clara. This is a great accomplishment. He went on to say, however, that since your husband is on the faculty and gets a good salary, we are not going to increase your salary. So when I came home, I told my husband, where upon he called the dean, who called the University president, who said, you be sure she gets the same salary or higher than the highest one you've ever given a new associate professor in medicine. Thus, my pay issue was immediately resolved. It's hard to believe that's a true story, except I saw similar things myself as I was going up, and they were getting corrected, at least. Well, anyway, we're running out of time. And I just want to thank you for all the things you've done, the contributions you've made to the field. Your legacy is incredible, in my opinion. And I think people will long remember what Clara Bloomfield has done in terms of changing how we treat leukemia, changing the treatment of leukemia into groups of patients who traditionally weren't treated, like older folks, and probably the pioneering work you did in bringing women into science and medicine, especially in oncology. So thanks for taking time to speak with me today. And I think people are going to be really thrilled to listen to your story as they drive to work and say, wow, I didn't realize that that's what it was like back in the old days. So thanks so much. And I think, especially, our young and translational scientists, particularly women, and also, most importantly, our patients deserve to give you credit for all of the things you've done and [? thanks ?] you've done. Until next time, thank you for listening to this JCO's Cancer Stories-- The Art of Oncology podcast. If you enjoyed what you heard today, don't forget to give us a rating or review on Apple Podcasts or wherever you listen. While you're there, be sure to subscribe so you never miss an episode. JCO's Cancer Stories-- The Art of Oncology podcast is just one of ASCO's many podcasts. You can find all the shows at podcast.asco.org. [MUSIC PLAYING]  

Dr. Greene and Dr. Edge will discuss the TNM staging system and its relevance to breast cancer management. Dr. Edge was Editor-in-Chief of the 7th Edition of the AJCC Cancer Staging Manual published in 2009 and co-author with Armando E. Giuliano and Gabriel N. Hortobagyi of the ASO editorial, “Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer” Dr. Edge is the Vice President for Healthcare Outcomes Policy and Professor of Oncology at the Roswell Park Cancer Institute. Dr. Edge also serves as Immediate Past Chair of the Commission on Cancer, on the Cancer Support Community Policy Institute of the National Advisory Board.

Dr. Rizk practices as a Breast Surgeon at Saint Francis Hospital, Hartford, CT, where she is also the Director of the Comprehensive Women’s Health Center. She is a graduate of the University of Rochester, where she earned her B.S. in Neuroscience. She went on to receive her M.D. at SUNY Upstate Medical Center, completed General Surgery Residency at the Cleveland Clinic in Ohio, and a fellowship in Breast Disease at Brown University Women and Infant’s Hospital, Rhode Island. Dr. Rizk is truly passionate and caring about her work and patients. In her 13 years of practice she has served as faculty at Roswell Park Cancer Institute, SUNY Stony Brook, an St. Francis Hospital. She is dedicated to empowering her patients and their wellness as individuals. Dr. Rizk was featured as a commentator for breast health on Fox News in 2014 and 2015, and contributed a chapter to the book “Surviving Cancer: Our Voices and Our Choices”. To name just a few of her clinical interests, she is interested in breast cancer treatment, nipple-sparing mastectomy, and breast conservation.

Ashley Stenzel (she/her) is a PhD candidate in cancer epidemiology at Roswell Park Cancer Institute in Buffalo, NY. We chat about her experience as a teen mom, turning her back on science only to come back, and her passion for science outreach and education. Plus, we debunk some myths and conspiracy theories about cancer, coming from a cancer researcher herself. Where you can find Ashley: Twitter Website Look out for her talk on the Story Collider podcast. Cancer Resources! United States: American Cancer Society & Minority Cancer Awareness Black Women's Health Imperative Latinas Contra Cancer National LGBT Cancer Network Sisters Network Inc. Canada: Canadian Partnership Against Cancer (and their study on low income patients) Canadian Cancer Society Support #InferiorinCanada, as we fundraise to get Angela Saini's Inferior into high schools across Canada! Check it out. You can find me (your host, Ive) on Twitter, Insta, and YouTube. Let's be friends! Any feedback on the show? Let us know on Twitter at @ScienceSucksPod. --- Support this podcast: https://anchor.fm/sciencesucks/support

Our guest today is Lakshmi Ramachandran completed her PhD in cell and molecular biology at Roswell Park Cancer Institute, SUNY Buffalo. She passionately worked in drug discovery before facing some personal struggles, taking a break from science and then coming back after 2 yrs. Re-entry was more challenging then she expected and this forced her in the direction of advocating for women in STEM. Today she lives in Singapore & is an author, a professional science communicator and a professional speaker. Lakshmi & her husband also bravely rescued her neighborhood during India's worst floods in 2018. Let's talk to Lakshmi to uncover her amazing STEM story.    Links:  https://storiesinscience.org/2017/09/23/unconventional-yet-common-science-career-path/ Connect with Lakshmi: www.linkedin.com/in/lakshmiramachandranphd   Lakshmi's Book: https://www.amazon.com/Roomies-Foodies-Cooking-Students-Abroad-ebook/dp/B0196UDNYE  

Sunday March 4th, 2018 Author, podcaster, and activist Ali A. Rizvi joins us to discuss his book "The Atheist Muslim, A Journey from Religion to Reason".   Ali A. Rizvi is a writer, activist, public speaker, and physician. Ali grew up in Libya, Saudi Arabia, and Pakistan, as part of a progressive Muslim family, before he moved permanently to Canada in his twenties. As a physician, he trained in pathology (with fellowship in oncologic pathology) at SUNY Buffalo and the Roswell Park Cancer Institute, and also holds a master of science degree in biochemistry from McMaster University. Today, he works in medical communications. Ali is an avid and vocal advocate for secularism, science, and reform, particularly in the Muslim community. He has been featured on CNN, in The New York Times, The Atlantic, The Huffington Post, CBC, New York Post, and a range of other major media outlets. You can find Ali's book here: http://atheistmuslim.com/book/ You can find Ali's podcast, Secular Jihadists podcast, on Apple Podcasts, Stitcher, and Google Play: http://secularjihadists.libsyn.com/  Other resources listeners might be interested in: Muslimish on Twitter: https://twitter.com/Muslimish  and Ex-Muslims of North America: https://www.exmna.org/ If you enjoyed this show, we'd love to have you come back next week for another fantastic episode.  You can catch Atheist Talk live, every Sunday Morning at 9:00am Central on AM 950 KTNF or online at http://www.am950radio.com/listen-live/ Contact us during the show with questions or comments at (952) 946-6205 or contact us anytime via radio@mnatheists.org or tweet us anytime at @atheiststalk Support the show by visiting https://www.patreon.com/AtheistTalk

In the latest installment of our special series “Innovation Happens,” we take a look at CIMAvax, a promising lung cancer vaccine developed in Cuba that is getting a lot of attention here in the United States. It is being studied in an FDA approved clinical trial at Roswell Park Cancer Institute-- the first Cuban therapy to be tested in the US. Our guest is Dr. Mary Reid, the Director of Cancer Screening and Survivorship at Roswell Park and a key member of the team that is collaborating with Cuban scientists on CIMAvax. Dr. Reid shares with us the history of the vaccine and how it could spur a new age of American-Cuban medical collaboration.

Dr. Lynne Maquat is the J. Lowell Orbison Distinguished Alumni endowed Professor in the Department of Biochemistry and Biophysics, Professor within the Cancer Center, and Director of the Center for RNA Biology at the University of Rochester. Lynne has a Labrador retriever who she loves taking on walks through the lovely parks and woods in Rochester, New York. She also enjoys exercising through yoga, lifting weights, and doing cardio. Research in Lynne’s lab focuses on human diseases and what causes diseases in our cells. She is working to understand how cells function normally, determine what causes diseases, and develop treatments for diseases. In particular, she has been studying a process in cells that causes about one third of all inherited diseases, like cystic fibrosis and Duchenne muscular dystrophy, as well as one third of all acquired diseases, including cancer. She received her BA in Biology from the University of Connecticut and her PhD in Biochemistry from the University of Wisconsin-Madison. Lynne conducted postdoctoral research at the University of Wisconsin-Madison, and she worked as a faculty member at the Roswell Park Cancer Institute for 19 years before joining the faculty at the University of Rochester. Lynne has received numerous awards and honors during her career, including the International RNA Society Lifetime Achievement in Science Award, the Canada Gairdner International Award, the William Rose Award from the American Society of Biochemistry and Molecular Biology, the Athena Award from the Womenen’s Council of the Rochester Business Alliance, a MERIT Award from the NIH, the Presidential Diversity Award from the University of Rochester, the RNA Society Lifetime Achievement Award in Service, and many others. She was also named a Member of the U.S. National Academy of Sciences, a Fellow of the American Association for the Advancement of Science, a Fellow of the American Academy of Arts and Sciences, and a Batcheva de Rothschild Fellow of the Israel Academy of Sciences and Humanities. Lynne discusses her experiences in life and science with us in this interview.

Today we're highlighting Candace Johnson, CEO of Roswell Park Cancer Institute, who was recently named #1 of the Power 100 ranking by Buffalo Business First. In this episode, Candace talks with Matt about their innovative partnership with Cuba, the surprising ease of recruiting stellar researchers & physicians to Buffalo, Roswell's role as an economic driver for the region, and why patients should be the center of the universe. If you enjoyed this episode, you may also like Episode 19 "Finding the Right People" with Norma Nowak, founder of Empire Genomics and fellow Power 100 nominee. 

Hear from Norma Nowak, entrepreneur, scientist, innovator and director of UB's NYS Center of Excellence in Bioinformatics and Life Sciences. Norma talks about the road that led her to founding Empire Genomics, a spin out company from research developed at Roswell Park Cancer Institute; the critical role her research played in the Human Genome Project; and how the advancement of technology has accelerated the genomics field in ways she couldn't have imagined.

Dd you know that 70 to 80 percent of people will experience at least one episode of back pain in their lifetimes? Find out what you can do about your aching back and sore neck. Sandeep Johar, D.O., M.S., Neurosurgery, Orthopaedics & Spine Specialists (NOSS) joins host Robin Sills, RN, Physician Liaison, on “Medically Speaking” to talk about back and neck pain, the difference between acute and chronic pain, plus interventional management, including how it works, when it’s appropriate and the latest techniques. Dr. Johar has a master’s degree in physiology from Roswell Park Cancer Institute and received his medical degree from New York College of Osteopathic Medicine. He completed an internship and residency in emergency medicine at Upstate Medical University in Syracuse, a fellowship in sports medicine at the University of Rochester School of Medicine, and a fellowship in spine, sports and musculoskeletal medicine at the University of Florida.

Candace Johnson, CEO of Roswell Park Cancer Institute, talks with Matt about their innovative partnership with Cuba, the surprising ease of recruiting stellar researchers & physicians to Buffalo, Roswell's role as an economic driver for the region, and why patients should be the center of the universe.

Philip McCarthy, MD is the director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute in Buffalo, New York. He has been in oncology practice for more than 20 years. His research interests include patient outcomes after blood and marrow transplantation, blood and marrow stem cell isolation, and preclinical models of bone marrow transplantation. He spoke with Oncology Data Advisor about when to consider bone marrow transplantation (BMT), barriers to transplant referrals, the improved safety of unrelated donor transplants, and the use of transplants in elderly patients. Discussion Notes: On the types of transplants and when to consider this procedure [1:10] On the types of lymphoma that may benefit most from BMT [8:01] On the underutilization of BMT and why eligible patients may not receive transplant referrals [10:40] On how oncologists can address barriers to transplant referral [14:55] On the improved outcomes of unrelated donor transplants [16:48] On the use of BMT in elderly patients [21:48]

Stem cell transplants will continue to be a staple of multiple myeloma therapy because they are highly effective. But can we add something before or after transplant to make them even more powerful? With new maintenance therapies showing greater overall survival and with new drugs and immunotherapies in the mix, what can we add on the front or back end to make transplant even better? Hear from Dr. Philip McCarthy from the Roswell Park Cancer Institute, a stem cell transplant expert, about the use of maintenance treatments and up-front options that can give patients more durable outcomes.

Patients who have high-risk genetic features like the 14;16 translocation need new treatment options. Dr. Carmen Baldino of Jasco Pharmaceuticals and Dr. Kelvin Lee of the Roswell Park Cancer Institute are working on a potentially curative solution for patients with this high-risk translocation using a PIM2 Kinase inhibitor called JP-11646. Learn more about this proposal for the Myeloma Crowd Research Initiative to address the unmet needs for high-risk patients.

Becky Freeman, TC's Assistant Editor; Web & New Media, talks to Andrew Hyland, Roswell Park Cancer Institute, Buffalo, about his paper looking at the associations between tobacco exposure and adverse pregnancy outcomes. Read the full paper: Associations of lifetime active and passive smoking with spontaneous abortion, stillbirth and tubal ectopic pregnancy: a cross-sectional analysis of historical data from the Women's Health Initiative http://goo.gl/IM1Keh

Join us as we talk with Dr. Sarah Holstein, MD, PhD of the Roswell Park Cancer Institute about her work to outsmart myeloma resistance and her work to target the bone marrow microenvironment via a variety of pathways. 

Join us as we talk with Dr. Sarah Holstein, MD, PhD of the Roswell Park Cancer Institute about her work to outsmart myeloma resistance and her work to target the bone marrow microenvironment via a variety of pathways. 

Listen as we talk with Dr. Phillip McCarthy of the Roswell Park Cancer Institute about his work in immunotherapy, transplantation and myeloma care. 

Guest: Moray Campbell, PhD, Assoc. Professor, Roswell Park Cancer Institute Bio and Contact Info Listen (5:35) How much bioinformatics does the new biologist need?

Joining CSC for part 2 of our tissue collection and research radio show is Dr. Stephen Edge, the immediate past Chair of the American College of Surgeons Commission on Cancer and Dr. Carl Morrison, Executive Director of the Center for Personalized Medicine at the Roswell Park Cancer Institute. This sequel will focus on tissue sampling, why it's important and the advancement of research, diagnosis and treatment of diseases, both now and into the future. Join us for an in-depth look into tissue collection and a deeper look into the topic!

Dr Samantha Sobus talks with ecancer at the 2013 AACR Annual Meeting in Washington DC about the continuation of nicotine use during radiation therapy. Continuing to smoke after cancer diagnosis has dramatic effects on both treatment and outcome, including drug resistance, tumour growth and increasing side effects of treatment.

rofessor John Gribben from Barts and The London Trust Cancer Centre, UK, is joined by Professor Myron Czuczman, Roswell Park Cancer Institute from Roswell Park Cancer Institute, New York, USA, and Professor Wolfram Brugger from Villingen-Schwenningen, Germany, at ASH 2012 to talk to ecancer.TV about hot topics in lymphoma from ASH 2012. Professor Czuczman points to the promise with lenalidomide in combination, eg, in indolent lymphomas, and data with new agents such as GS-1101, ibrutinib, PTK inhibitors and PI3K inhibitors. He also comments on the chemo-free approach to treatment and outlines some of these regimens in on-going clinical trials. Professor Czuczman also notes the importance of determining the order of therapies given, and of long-term follow-up in clinical trials. Professor Brugger notes the need for combination regimens with newer agents and the challenge of finding which combinations work best. Professor Brugger also talks about the use of bendamustine in combination with some of the novel agents presented at ASH 2012, eg, NHL1 data. The experts emphasise the need for study investigators to get together post-ASH 2012 to co-ordinate the way forward in clinical trials following the wealth of new data. They also comment on the clinical, safety, ethical and economic consequences of long-term treatment in lymphoma, on the value of drug-free holidays, on compliance issues with new oral agents and on finding the balance between efficacy, toxicity and quality of life in lymphoma management. They discuss data presented for the newer treatments in different sub-types of lymphoma, eg, mantle cell lymphoma. Also on advances with targeted therapies, with summaries of data on new antibodies to direct therapies to the tumour cells. They discuss the important balance between aggressive vs. less aggressive therapy in different patients, and the future possibility of cure vs. long-term remission. Finally, the experts emphasise the palpable excitement in lymphoma from ASH 2012 and comment on where this might lead to.

Professor John Gribben from Barts and The London Trust Cancer Centre, UK, is joined by Professor Myron Czuczman, Roswell Park Cancer Institute from Roswell Park Cancer Institute, New York, USA, and Professor Wolfram Brugger from Villingen-Schwenningen, Germany, at ASH 2012 to talk to ecancer.TV about hot topics in lymphoma from ASH 2012. Professor Czuczman points to the promise with lenalidomide in combination, eg, in indolent lymphomas, and data with new agents such as GS-1101, ibrutinib, PTK inhibitors and PI3K inhibitors. He also comments on the chemo-free approach to treatment and outlines some of these regimens in on-going clinical trials. Professor Czuczman also notes the importance of determining the order of therapies given, and of long-term follow-up in clinical trials.

Join us this week as we welcome county music singer songwriter, Amanda Nagurney. Hailing from Mount Juliet, TN., she recently released her new album titled “Gone” on October 25th, 2011. Amanda has sung the National Anthem for the Buffalo Bills, Sabres, Nashville Predators, Louisville Bats (Slugger Field), World’s Toughest Rodeo and opened for many Nashville Recording Artists such as Sammy Kershaw, Bucky Covington, Travis Tritt, The Band Perry, and many others. Amanda has performed for many local charities including Roswell Park Cancer Institute, Connecticut Street Armory, Fort Drum in Watertown, Woman & Children’s Hospital of Buffalo, Jim Kelly’s Hunter’s Hope, The Red Cross, Make A Wish Foundation, and many others. Also Amanda has performed shows for the troops including Walter Reed Army Hospital performing for the Wounded Warriors along with the USO. We will talk to Amanda about her upcoming schedule, get a behind the scenes look at her music, feature her latest songs and ask her to share her efforts to support the troops. Please be sure to visit Amanda Nagurney at http://amandanagurney.com/ and spread the word. Fans are welcome to call in and chat live with Amanda during the show. If you would like to participate in the live chat during the show, you must sign up on the show site first and then log in during the show. More great music for a really great cause! And as always we will give shout outs to our deployed military listeners. This is sure to be a terrific show so be sure to join us, Sunday August 5th 2012 at 4:00 PM EST! Our message to the troops....WE do what we do, because YOU do what you do.

Learn How The Intake Of Raw Broccoli May Improve Bladder Cancer Survival Dr. Li Tang is an Assistant Member in the Department of Cancer Prevention and Control at Roswell Park Cancer Institute. Her educational background is in medicine, nutrition, cancer biology, and epidemiology. She obtained her Ph.D. degree in Cancer Prevention and Pathology, and received postdoctoral training in Nutritional Epidemiology. Dr. Tang is engaged in the molecular epidemiological study of cancer, with focus on cancer recurrence and survival. Her research interest is to understand the interactive roles of genetic and dietary factors in cancer prognosis. Her primary focus is on cruciferous vegetables and their key anti-cancer effectors, the phytochemical isothiocyanates. Dr. Tang's recent publications: "Intake of Cruciferous Vegetables Modifies Bladder Cancer Survival." Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1806-11. Epub 2010 Jun 15 and "Consumption of Raw Cruciferous Vegetables is Inversely Associated With Bladder Cancer Risk." Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):938-44. Download or Open:

Guests: James R. Marshall PhD, Roswell Park Cancer Institute 877-ASK-RPCI )Ms. Gretchen Leffler, American Cancer Society WNY National 800-ACS-2345 (800-227-2345)Cancer Prevention & Research Foundation CDC – Cancer Prevention & Control

Guests: James R. Marshall PhD, Roswell Park Cancer Institute 877-ASK-RPCI ) & Ms. Gretchen Leffler, American Cancer Society WNY  National 800-ACS-2345 (800-227-2345)Cancer Prevention & Research Foundation CDC – Cancer Prevention & Control